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1. INTRODUCTION {#mgg3569-sec-0005}
===============

Mediator of RNA polymerase II transcription subunit 12 homolog (*MED12*) encodes a core component of a multi‐subunit mediator complex, which includes MED12, MED13, cyclin C, and CDK8 (Yin & Wang, [2014](#mgg3569-bib-0028){ref-type="ref"}). Mediator is a large, evolutionarily conserved protein complex that plays an important role in gene regulation (Yin & Wang, [2014](#mgg3569-bib-0028){ref-type="ref"}). The mediator complex consists of approximately 30 subunits that are assembled into four functional modules interacting with signaling proteins in the vertebral endoderm (Shin et al., [2008](#mgg3569-bib-0021){ref-type="ref"}) and neuronal development (Wang, Yang, Uno, Roeder, & Guo, [2006](#mgg3569-bib-0026){ref-type="ref"}) and the canonical Wnt signaling pathway (Rocha, Scholze, Bleiss, & Schrewe, [2010](#mgg3569-bib-0019){ref-type="ref"}). GLI family zinc family protein 3 (GLI3) binds directly to the PQL domain of MED12, which suppresses the enhanced GLI3‐dependent transactivation induced by Sonic hedgehog (SHH) signaling (Zhou, Kim, Ishii, & Boyer, [2006](#mgg3569-bib-0029){ref-type="ref"}). SHH signaling has critical functions in the development of the central nervous system including neural tube patterning, neuronal cell differentiation and survival (Ho & Scott, [2002](#mgg3569-bib-0008){ref-type="ref"}).

*MED12* mutations have been associated with a wide phenotypic spectrum of *MED12*‐related disorders (Charzewska et al., [2018](#mgg3569-bib-0003){ref-type="ref"}). Somatic mutations in *MED12* have been reported in leiomyosarcoma (Ravegnini et al., [2013](#mgg3569-bib-0016){ref-type="ref"}) and prostate cancer (Kämpjärvi et al., [2015](#mgg3569-bib-0010){ref-type="ref"}). Germline *MED12* mutations were originally found in patients with FG and Lujan syndromes (Risheg et al., [2007](#mgg3569-bib-0018){ref-type="ref"}; Schwartz et al., [2007](#mgg3569-bib-0020){ref-type="ref"}) and later in patients with X‐linked Ohdo syndrome and isolated XLID disorders (Bouazzi, Lesca, Trujillo, Alwasiyah, & Munnich, [2015](#mgg3569-bib-0001){ref-type="ref"}; Callier et al., [2013](#mgg3569-bib-0002){ref-type="ref"}; Isidor et al., [2013](#mgg3569-bib-0009){ref-type="ref"}; Langley et al., [2015](#mgg3569-bib-0011){ref-type="ref"}; Lesca et al., [2013](#mgg3569-bib-0012){ref-type="ref"}; Tzschach et al., [2015](#mgg3569-bib-0023){ref-type="ref"}; Vulto‐van Silfhout et al., [2013](#mgg3569-bib-0025){ref-type="ref"}; Yamamoto & Shimojima, [2015](#mgg3569-bib-0027){ref-type="ref"}). Mutations that cause FG syndrome (p.R961W) and Lujan syndrome (p.N1007S) were found to compromise the mediator‐imposed constraint on GLI3‐dependent SHH signaling and result in increased transcript levels for multiple GLI3 target genes in lymphoblasts from patients (Zhou et al., [2012](#mgg3569-bib-0030){ref-type="ref"}). How GLI3--SHH‐signaling defects relate to the complex clinical phenotypes of *MED12*‐associated XLID syndromes are not known.

We report genetic and functional characterizations of four *MED12* mutations in patients with XLID disorders. Patients with LS‐domain mutations show ID and congenital malformations overlapping with FG and Lujan syndromes. Transcript levels of three SHH/GLI3‐signaling genes, *BMP4*(OMIM112262), *CREB5*, *NEUROG2* (OMIM606624), were found to be significantly elevated in lymphoblasts from patients with these mutations. The patient with a change in the L domain only had elevated expression of *BMP4* and presented with ID and predominant psychiatric phenotypes. These results expand genotype and phenotype spectrums of *MED12*‐mediated XLID syndromes and support a critical role of MED12‐regulated Gli3‐dependent SHH signaling in the expression of disease phenotypes.

2. MATERIALS AND METHODS {#mgg3569-sec-0006}
========================

2.1. Study patients and controls {#mgg3569-sec-0007}
--------------------------------

Patients with XLID and control males with normal cognitive function were recruited by the Greenwood Genetic Center (Greenwood, SC) and the Johns Hopkins University (Baltimore, MD). Human subject research protocols for these studies were approved by Institutional Review Boards (IRBs) at the respective institutions. An informed consent was obtained from each study patient and/or their parents or legal guardians. These patients were all evaluated by clinical geneticists and underwent comprehensive laboratory studies for ID. All patients were found to have a normal karyotype, negative molecular testing for fragile X syndrome, and a negative screen for common inborn errors of metabolism. For each individual, 5--10 ml of blood was collected to establish EB‐transformed lymphoblast cell lines. Genomic DNA samples from affected probands males with XLID were used for sequencing and mutation screening. A cohort of \>800 males with normal cognitive function from the Greenwood Genetic Center and Johns Hopkins University were used as controls. Additional reference data include the male portion of samples (*n* = 525) from the 1,000 Genomes project (Integrated Phase 1, version 3:20101123).

2.2. X chromosome exome sequencing and exon‐based resequencing {#mgg3569-sec-0008}
--------------------------------------------------------------

Sequence libraries were prepared using a TruSeq^TM^ Genomic DNA Library Preparation kit (Illumina), enriched for the human X chromosome Exome using a SureSelect Target Enrichment kit (Agilent), and sequenced using the 75 bp pair‐end sequence module on the HiSeq2000 (Illumina). Alignment of the fastq reads, base recalibration, and variant calling were completed using Bowtie2 and Unified Genotyper (GATK). Disease‐causing mutations were enriched using the nonclinical portion of the dbSNP, the male‐restricted portion of the 1,000 Genomes, Exome Variant Server datasets, and an affected sib‐pair/cross‐cohort‐based algorithm (Niranjan et al., [2015](#mgg3569-bib-0014){ref-type="ref"}). Evolutionary conservation of the amino acid residues involved in the identified mutations was evaluated by multiple sequence alignment of HomoloGene (<http://www.ncbi.nlm.nih.gov/homologene/>). Standard bioinformatics algorithms including SIFT (<http://sift.jcvi.org>) and PolyPhen‐2 (<http://genetics.bwh.harvard.edu/pph2/index.shtml>) were used to predict the functional impact of the identified mutations (Niranjan et al., [2015](#mgg3569-bib-0014){ref-type="ref"}). Additional exon‐based resequencing was conducted to identify novel *MED12* mutations in patients with intellectual disability and a pedigree consistent with X‐linked inheritance (Raymond et al., [2007](#mgg3569-bib-0017){ref-type="ref"}). Sanger sequencing was used for validation, segregation analysis, and polymorphism studies of each mutation using the BigDye Terminator v3.1 Cycle Sequencing Kit on an ABI3100 automatic DNA analyzer (Applied Biosystems) following manufacturer\'s instruction. Variant analysis of *MED12* (NM_005120.2) was completed using standard sequence alignment software (CodonCode and MacVector) followed by manual investigations of the chromatograms.

2.3. Real‐time quantitative PCR analysis for transcript levels of SHH‐signaling genes {#mgg3569-sec-0009}
-------------------------------------------------------------------------------------

EBV‐transformed lymphoblastoid cell lines from patients and controls were cultured in RPMI 1640 medium with 15% FBS (Sigma) and 1% penicillin--streptomycin (100 U penicillin; 0.1 mg/ml streptomycin) at 37°C, 10% CO~2~. Cells were harvested at log phase. Total RNA was prepared from cultured lymphoblasts from individual patients and normal controls using a Qiagen RNA preparation kit. cDNA from these samples was synthesized using a M‐MLV RT kit (Promega). Real‐time qPCR was conducted using an absolute SYBR Green mix (Applied Biosystems) in an iCycler (BioRad). After initial denaturation at 95.0ºC for 3 min, the reaction was cycled for 35 times at 95.0ºC for 30 s and 60.0ºC for 45 s. Input samples were normalized using a simultaneous quantification of β‐actin. qPCR Primers used in this study are given in Table [S1](#mgg3569-sup-0002){ref-type="supplementary-material"}. Lymphoblast cell lines from three unrelated normal males and from the original Lujan family with a p.N1007S mutation were used as controls. Each data set for the transcript levels was generated from triplicate studies. Statistical analyses of qPCR data were performed using two‐tailed *t* test for comparison of the means of two independent samples. Data were presented as mean ± *SEM*; *p* \< 0.05 was considered statistically significant.

3. RESULTS {#mgg3569-sec-0010}
==========

3.1. Identification and pedigree analysis of *MED12* mutations in XLID families {#mgg3569-sec-0011}
-------------------------------------------------------------------------------

Exon resequencing of 718 X‐linked genes (Tarpey et al., [2009](#mgg3569-bib-0022){ref-type="ref"}) found a c.3884G\>A; p.R1295H mutation in two affected brothers (II‐3 and II‐6) and their mother who is heterozygous (K9338) (Figure [1](#mgg3569-fig-0001){ref-type="fig"}a). Sequencing of *MED12* in a cohort of XLID families identified c.617G\>A; p.R206Q mutation in an affected male and his unaffected mother (K8935) (Figure [1](#mgg3569-fig-0001){ref-type="fig"}b) and a c.2692A\>G; p.N898D mutation in an affected male and his unaffected mother in a family suspected to have FG syndrome (K9467) (Figure [1](#mgg3569-fig-0001){ref-type="fig"}c). X chromosome exome sequencing identified a c.3640C\>T; p.R1214C in two affected brothers and their unaffected mother in an XLID family (L08--2677) (Niranjan et al., [2015](#mgg3569-bib-0014){ref-type="ref"}) (Figure [1](#mgg3569-fig-0001){ref-type="fig"}d). The p.N898D, p.R1214C, and p.R1295H mutations are located in the LS domain while the p.R206Q mutation is located in the L domain of MED12 (Figure [2](#mgg3569-fig-0002){ref-type="fig"}a). All four mutations involve highly conserved amino acid residues during evolution, and none was found in \>1,325 normal X chromosomes (Figure [2](#mgg3569-fig-0002){ref-type="fig"}b). The Combined Annotation Dependent Depletion (CADD) scores for all four mutations are in the range of 23.2 to 31 suggesting a high likelihood of deleterious effects (Table [1](#mgg3569-tbl-0001){ref-type="table"}) (GRCh37‐v1.4, <https://cadd.gs.washington.edu>).

![Pedigree Analysis and Clinical Features of XLID Probands with *MED12* Mutations. Panel a: Segregation of c.3884G\>A; p.R1295H in pedigree of K9338; confirmed genotypes (WT, G; mutation, A) are indicated below individual symbols; skewed X chromosome inactivation data in female carriers are provided for II2, II4, III2. Facial features of one affected male are shown. Panel b: Segregation of c.617G\>A; p.R206Q in pedigree K8935. Confirmed genotypes (WT, G; mutation, A) were shown below the affected male. Facial features of the affected male are shown. Panel c: Segregation of c.2692A\>G; p.N898D in pedigree K9467. Confirmed genotypes (WT, A; mutation, G) are indicated below individual symbols; data for skewed X chromosome inactivation are provided for II2, II3, and II4. Facial features of the affected male are shown. Panel d: Segregation of c.3640C\>T; p.R1214C in pedigree of LO8--2677. Confirmed genotypes (WT, C; mutation, T) are indicated below individual symbols. For all pedigrees: square symbol, male; circle symbol, female; open symbol, unaffected; filled symbol, affected; circle with a center dot, confirmed female carrier](MGG3-7-na-g001){#mgg3569-fig-0001}

![Disease‐causing *MED12* Mutations Involve Highly Conserved Amino Acid Residues and are Clustered around the Established Functional Domains. Panel a: Distribution of ID‐associated mutations over functional domains of MED12. Known ID‐associated mutations(Graham & Schwartz, [2013](#mgg3569-bib-0007){ref-type="ref"}) are presented above and the four mutations of *MED12* (NM_005120.2) in this study are below the symbols of protein domains. Note that 3 mutations p.N898D, p.R1214C, and p.R1295H are located within the LS domain where the recurrent mutations for FG and Lujan syndromes occur and one, p.R206Q, is located within the L domain. L, leucine‐rich domain; LS, leucine serine‐rich domain; PQL, proline‐, glutamine‐, and leucine‐rich domain; OPA, glutamine‐rich domain. Panel b. *MED12*mutations involve highly evolutionarily conserved amino acid residues as shown in a multispecies sequence alignment. Mutations responsible for FG, Lujan, and Ohdo syndrome are based on previously published studies(Graham & Schwartz, [2013](#mgg3569-bib-0007){ref-type="ref"})](MGG3-7-na-g002){#mgg3569-fig-0002}

###### 

Clinical features of MED12 mutations responsible for XLID syndromes

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Pedigree ID_Syndrome                                    FG syndrome                            Lujan syndrome                               XLID_K8935_II‐1                                  XLID_K9467_III‐1                                                     XLID_L08‐2677_II‐1                                                           XLID_L08‐2677_II‐2                                         XLID_K9338_II‐1                                                                          XLID_K9338_II‐6
  ------------------------------------------------------- -------------------------------------- -------------------------------------------- ------------------------------------------------ -------------------------------------------------------------------- ---------------------------------------------------------------------------- ---------------------------------------------------------- ---------------------------------------------------------------------------------------- --------------------------------
  GRCh37‐v1.4                                                                                                                                 ChrX:70340884                                    ChrX:70346825                                                        ChrX:70349228                                                                ChrX:70349228                                              ChrX:70349901                                                                            ChrX:70349901

  Mutation                                                                                                                                    c.617G\>A; p.R206Q                               c.2692A\>G; p.N898D                                                  c.3640C\>T; p.R1214C                                                         c.3640C\>T; p.R1214C                                       c.3884G\>A; p.R1295H                                                                     c.3884G\>A; p.R1295H

  CADD[a](#mgg3569-note-0001){ref-type="fn"}                                                                                                  23.2                                             26.2                                                                 31                                                                           31                                                         23.4                                                                                     23.4

  Evaluation Age (year)                                                                                                                                                                                                                                             15                                                                           17                                                         14                                                                                       11

  Weight (kg)                                                                                                                                                                                                                                                       5th centile                                                                  5th%                                                       failure to thrive                                                                        failure to thrive

  Height (cm)                                                                                                                                                                                                                                                       10 th centile                                                                5th%                                                       25th centile (at 54 years)                                                               60th centile (at 49 years)

  OFC (cm)                                                Relative macrocephaly                  Macrocephaly                                 Macrocephaly                                     \>97th centile                                                       50--75th centile                                                             10--25th centile                                           Macrocephalic                                                                            75th centile (at 49 years)

  Appearance                                                                                     Marfanoid habitus                            Height and weight \>97%tile                                                                                           Asthenic build                                                               Asthenic build                                             Asthenic build                                                                           Poor muscle bulk

  Motor Development                                                                                                                                                                            Delayed walking                                                      Delayed walking                                                              Delayed walking                                            Delayed; clumsy walking                                                                  Delayed; walking after 2 years

  Language Development                                                                                                                                                                         Delayed; first word at 3 years                                       Delayed speech                                                               Delayed speech                                             Speech unintellligible until 5 years                                                     Delayed speech

  Intellectual Disability                                 Moderate to severe                     Mild to moderate                             Mild to moderate (IQ 40--85)                     Mild to moderate (IQ 58)                                             Mild to moderate                                                             Mild to moderate                                           Mild to moderate (IQ 58)                                                                 Moderate

  Behaviors                                               Friendly personality\                  Hyperactivity\                               Aggression\                                      Psychological lability\                                              Friendly personality\                                                        Friendly personality\                                      Impulsiveness Restlessness\                                                              
                                                          Short attention span\                  Emotional lability\                          Panic disorders\                                 Short attention span\                                                Excessive talkativeness                                                      Excessive talkativeness                                    Temper tantrums                                                                          
                                                          Temper tantum                          Aggressiveness                               Agoraphobia                                      Easily frustrated                                                                                                                                                                                                                                                                                     

  Craniofacial                                            Tall forehead Frontal hair upsweep     Tall forehead                                                                                 Tall and broad forehead Frontal upsweep                              Tall forehead                                                                Tall forehead                                                                                                                                       

  Long and narrow face\                                   Long and narrow face\                                                               Maxillary hypoplasia                             Long and narrow face\                                                Long and narrow face                                                         Long face; prominent supraorbital ridge                    Long face with maxillary hypoplasia                                                      
  Maxillary hypoplasia                                    Maxillary hypoplasia                                                                                                                 Maxillary hypoplasia                                                                                                                                                                                                                                                                                  

  Hypertelorism; downslanting palpebral fissures          Downslanting palpebral fissures        Downslanting palpebral fissures              Downslanting palpebral fissures Hypertelorism\   Telecanthus                                                          Telecanthus                                                                  Epicanthus; downslanting palpebral fissures; cataract      Strabismus                                                                               
                                                                                                                                              Astigmatism, hyeropia                                                                                                                                                                                                                                                                                                                                  

  Small prominent ears with simplified helical pattern    Hypernasal speech                      Astigmatism, exotropia, and mild hyperopia   Small posteriorly rotated ears                   Normal ears                                                          Normal ears                                                                  Normal ears                                                                                                                                         

  Dental crowding Micro/retrognathia                      Dental crowding; micro/retrognathia                                                 Dental crowding and prognathism                                                                                                                                                                    High‐arched palate                                         High‐arched palate                                                                       

  Musculoskeletal                                         Pectus extracavatum\                                                                                                                                                                                      Mild pectus carinatum                                                        Severe pectus carinatum\                                   Thoracic kyphosis;                                                                       Marked thoracic kyphosis
                                                          Scoliosis\                                                                                                                                                                                                                                                                             Moderate scoliosis\                                                                                                                                 
                                                          Joint contracture                                                                                                                                                                                                                                                                      Mild contracture of elbows                                                                                                                          

  Broad thumb; syndactyly; persistent fetal finger pads   Long extensible digits; broad thumbs   Long hands (length \>97th%)                  Angulation of distal phalanges; broad big toes   Hand length: 25--50th centile\                                       Hand length: 25--50th centile\                                               Pes cavus                                                  Finger contractures at PIP joints; Hammer toes; wide gap between first and second toes   
                                                                                                                                                                                               Middle finger length: 50th centile Arm span‐to‐height ratio: 1.03\   Middle finger length: 25--50th centile Arm span‐to‐height ratio: 1.05\                                                                                                                                                           
                                                                                                                                                                                               Upper‐to‐lower segment ratio: 0.89                                   Upper‐to‐lower segment ratio: 0.71\                                                                                                                                                                                              
                                                                                                                                                                                                                                                                    Slender fingers; hyperextensibility; fifth finger clinodactyly; pes planus                                                                                                                                                       

  Gastrointestinal                                        Anal anomaly; constipation                                                                                                           Imperforate anus Constipation                                        Severe constipation; megacolon                                                                                                          Anal stricture and stenosis; umblical and inguinal hernia                                Constipation

  Genitourinary                                           Genitourinary anomaly                                                               Hydroceles                                       Cryptorchidism                                                                                                                                    Posteriour urethral valves                                 Undescended testicles                                                                    Undescended testicles

  Neurological                                            Hypotonia                              Hypotonia                                                                                     Hypotonia                                                            Seizure disorders; wide spaced gait                                          Seizure disorders                                          Uncoordinated gait; hearing loss                                                         Hypotonia; hearing loss

  Agenesis of corpus callosum                             Agenesis of corpus callosum                                                                                                          Normal head CT                                                       Normal head CT                                                               Agenesis of corpus callosum; enlarged ventricules on MRI                                                                                            
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Combined Annotation Dependent Depletion (CADD); <https://cadd.gs.washington.edu>

John Wiley & Sons, Ltd

3.2. Increased expression of SHH‐signaling genes in lymphoblasts with LS‐domain mutations {#mgg3569-sec-0012}
-----------------------------------------------------------------------------------------

Increased transcript levels for SHH‐signaling genes have been reported in cell lines from patients with FG and Lujan syndrome (Zhou et al., [2012](#mgg3569-bib-0030){ref-type="ref"}). We thus performed a real‐time qRT‐PCR quantification of transcript levels of three genes (*CREB5*, *BMP4*, and *NEUROG2)*in the SHH‐signaling pathway in lymphoblasts from patients with four *MED12* mutations (Figure [3](#mgg3569-fig-0003){ref-type="fig"}). Transcript levels for these genes are significantly increased for the three LS‐domain mutations. The L‐domain mutation, p.R206Q, shows only modest increase in the transcript of *BMP4* (Figure [3](#mgg3569-fig-0003){ref-type="fig"}). Expression of *HPRT1*, a house‐keeping gene not known to be regulated by SHH/GLI3 signaling, showed no significant difference in lymphoblast cell lines between normal controls and patients with these *MED12* mutations (Figure [S1](#mgg3569-sup-0001){ref-type="supplementary-material"}). These results support that the MED12‐LS domain plays a major role in the negative regulation of Gli3‐dependent SHH signaling (Zhou et al., [2012](#mgg3569-bib-0030){ref-type="ref"}), and these mutations found in patients with ID and congenital malformations show deleterious effects on MED12 function.

![Real‐time Quantitative PCR Analysis of Transcript Levels of Three SHH‐Signaling Genes in Lymphoblasts from Patients with XLID. Note that compared to normal control lymphoblasts (*n* = 3), the transcript levels for all three genes, *CREB5, BMP4, NEUROG2* in the SHH‐signaling pathway show a significant increase in lymphoblasts carrying three *MED12* mutations (p.N898D; p.R1214C; and p.R1295H) within the LS domain but minimal changes for the mutation, p.R206Q, within the L domain. N1007S is the lymphoblast cell line from the probands of the original Lujan syndrome family(Schwartz et al., [2007](#mgg3569-bib-0020){ref-type="ref"}). Means ± *SEM* from the triplicate studies of each lymphoblast cell line were shown. \*\*, *p* \< 0.01; \*\*\*, *p* \< 0.001](MGG3-7-na-g003){#mgg3569-fig-0003}

3.3. Expanding phenotypic spectrum of *MED12*‐related XLID disorders {#mgg3569-sec-0013}
--------------------------------------------------------------------

*MED12*‐related XLID disorders exhibit a wide phenotypic spectrum in impairment of cognition, behavioral defects, and multiple congenital anomalies (Graham & Schwartz, [2013](#mgg3569-bib-0007){ref-type="ref"}). "The patient with p.N898D mutation presented with macrocephaly, tall and broad forehead, downslanting palpebral fissures, small and posteriorly rotated ears, broad big toes, imperforate anus and constipation, and behavioral profile that mostly resemble patients with FG syndrome. Patients with p.R1214C and p.R1295H mutations presented with features that resemble both Lujan and FG syndromes. These features include craniofacial features, behavioral profile, anal anomalies, and severe constipation that are common in patients with FG syndrome as well as long and thin face, high‐arch palate, asthenic body build, reduced muscle mass, long and slender fingers, joint hyperextensibility that are seen in patients with Lujan syndrome. The patient with p.R206Q mutation presented with ID and predominant neuropsychiatric phenotype but without significant dysmorphic features or congenital malformations of either FG or Lujan syndromes (Table [1](#mgg3569-tbl-0001){ref-type="table"})."

4. DISCUSSION {#mgg3569-sec-0014}
=============

Classical features of FG syndrome include ID, craniofacial features such as macrocephaly, prominent forehead, hypertelorism, downslanting palpebral fissures, small ears, musculoskeletal anomalies such as pectus deformities, broad thumbs, gastrointestinal defects such as anal anomaly with severe constipation, and a characteristic behavioral profile with friendly personality and short attention span (Clark et al., [2009](#mgg3569-bib-0004){ref-type="ref"}; Opitz & Kaveggia, [1974](#mgg3569-bib-0015){ref-type="ref"}). A recurrent mutation, p.R961W, in the MED12‐LS domain was identified in the original and five additional families with clinical features suggestive of FG syndrome (Risheg et al., [2007](#mgg3569-bib-0018){ref-type="ref"}). Patients from the original Lujan syndrome family presented with X‐linked intellectual disability, hypotonia, macrocephaly, marfanoid habitus with long fingers with extensible joints, craniofacial features such as long and narrow face, high‐arched palate with hypernasal voice, and structural brain anomalies such as agenesis of corpus callosum (Lujan, Carlin, & Lubs, [1984](#mgg3569-bib-0013){ref-type="ref"}). A single missense mutation in MED12‐LS domain, N1007S, has been identified in the original Lujan syndrome family (Schwartz et al., [2007](#mgg3569-bib-0020){ref-type="ref"}). The patient with p.N898D mutation presented with features that mostly resemble FG syndrome; patients with p.R1214C and p.R1295H mutations presented with features that overlap with FG and Lujan syndromes; the patient with p.R206Q mutation showed severe psychiatric phenotype but without characteristic dysmorphic features or malformations of either FG syndrome or Lujan syndromes (Table [1](#mgg3569-tbl-0001){ref-type="table"}). Taken together, our current studies on these four *MED12* mutations expand the genotype and phenotype spectrums of the *MED12*‐related X‐linked ID disorders.

MED12 consists of several structurally and functionally defined domains including a N‐terminal leucine‐rich domain (L), a leucine‐ and serine‐rich domain (LS), a proline‐, glutamine‐, and leucine‐rich domain (PQL), and a C‐terminal opposite paired domain (OPA). The PQL domain mediates protein--protein interaction while function for other domains remain largely unknown (Zhou et al., [2006](#mgg3569-bib-0029){ref-type="ref"}). Classical FG and Lujan syndromes are caused by mutations in the LS domain, which is highly conserved (Figure [2](#mgg3569-fig-0002){ref-type="fig"}a). Previous studies have shown that *MED12* mutations in FG and Lujan syndromes disrupt a mediator‐imposed constraint on GLI3‐dependent SHH signaling (Zhou et al., [2012](#mgg3569-bib-0030){ref-type="ref"}). Expression levels of multiple SHH/GLI3 target genes including *GLI3, ASCL1, BMP4*, *CREB5*, and *NEUROG2*were significantly elevated in patients' lymphoblast cell lines (Zhou et al., [2012](#mgg3569-bib-0030){ref-type="ref"}). Increased expression of these genes was inhibited by a SHH antagonist, cyclopamine, suggesting that their induction was SHH/GLI3 dependent (Zhou et al., [2012](#mgg3569-bib-0030){ref-type="ref"}).

By examining transcript levels of three Gli3‐dependent SHH‐signaling genes, *CREB5*, *BMP4*, and *NEUROG2,*in lymphoblasts, we found that p.N898D, p.R1214C, and p.R1295H mutations are associated with increased expression of all three genes. Interestingly, p.N898D mutation was found to associate with a significant increase in expression of *BMP4* but moderate increase in expression of *NEUROG22.*In contrast, p.R1214C and p.R1295H mutations were found to associate with significant increase in *NEUROG2* but moderate increase in *BMP4*. p.R206Q was found to associate with a mild increase in the expression of *BMP4* only. GLI3‐dependent SHH‐signaling pathway plays a critical role in development of multiple organs including brain, neural tube, developing limbs, and the gut (Villavicencio, Walterhouse, & Lannaccone, [2000](#mgg3569-bib-0024){ref-type="ref"}). We speculate that severe disturbance in SHH‐signaling genes likely play an important role in craniofacial anomalies and multiple organ malformations in these patients. We further speculate that differences in the expression profile of SHH‐signaling genes potentially contribute to variable expression of phenotypes in patients with *MED12*‐related XLID syndromes.

The Ohdo syndrome is defined by several mutations in LS and PQL domains (p.R1148H, p.S1165P, p.A1383T, p.H1729N). Core clinical features of patients include moderate to severe intellectual disability, autistic behaviors, craniofacial anomalies such as microcephaly, blepharophimosis, prominent and bulbous nose, ear anomalies, and moderate to severe hypotonia. Skeletal, gastrointestinal, and genital urinary anomalies that are common in the FG‐Lujan syndrome spectrum are relatively mild or absent in patients with Ohdo syndrome. The molecular mechanisms that underlie Ohdo syndrome have not been fully characterized. MED12 has also been found to play key roles in the regulation of REST‐dependent epigenetic silencing of neuronal gene expression (Ding et al., [2008](#mgg3569-bib-0005){ref-type="ref"}) and immediate early gene expression (Donnio et al., [2017](#mgg3569-bib-0006){ref-type="ref"}). Systematic functional characterizations of these mutations are warranted.
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